A proposed system for classifying psychotropic drugs

Journal of Psychosocial Nursing and Mental Health Services

Volumn 52, Issue 12, 2014, Pages 13-16

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

CLASSIFICATION; HUMAN;

HUMANS; PSYCHOTROPIC DRUGS;

EID: 84928379445     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20141118-05     Document Type: Article

References (7)

1. Brauser, D. (2014, November 3). New psychotropic drug classification system unveiled. Medscape Medical News. Retrieved from http://www.medscape.com/viewarticle/834238
2. Gillman, P.K. (2006). A systematic review of the serotonergic effects of mirtarapine in humans: Implications for its dual action status. Human Psychophaimacology, 21, 117-125.
3. Howland, R.H. (2008). Understanding the clinical profile of a drug on the basis of its pharmacology: Mirtarapine as an example. Journal of Psychosocial Nursing ami Menial Health Services, 46(12), 19-23.
4. Howland, R.H. (2012). Off-label medication use. Journal of Psychosocial Nursing and Mental Health Services, 50(9), 11-13. doi:10.3928/02791695-20120807-05
5. Howland, R.H. (2014a). Atypical antipsychotics are not all alike: Side effects and risk assessment. Journal of Psychosocial Nursing and Mental Health Services, 52(9), 13-15. doi:10.3928/02793695-20140820-01
6. Howland, R.H. (2014b). Mortality risk of mirrazapine: Guilt by association.' JAMA Psychiatry. 71, 585-586. doi:10.1001/jamapsychiatry.2013.4582
7. Zohar, J., Nutt D.J., Kupfer, D.J., Moller, H.J., Yamawaki, S., Spedding, M., & Stahl, SM. (2014). A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology, 24, 1005-1014. doi:10.1016/j.euroneuro.2013.08.004